ATM and neoplasm: This regimen induced growth delay in the ATM-WT and tumour regression in the ATM-KO tumours (Fig. 6b), thus demonstrating proof of principle that low-dose gemcitabine can be used as a sensitiser to AZD6738 in vivo.